<?xml version="1.0" encoding="UTF-8"?>
<p>The HBVr risk for chronically infected HBV patients on ABA treatment has been explored only in small retrospective studies. In a study by Kim and colleagues,
 <sup>
  <xref rid="bibr77-1759720X20912646" ref-type="bibr">77</xref>
 </sup> four of eight HBsAg positive patients who did not received prophylaxis developed HBVr after a mean period of 10.5â€‰months. An Italian retrospective multicenter study collected data on 72 RA patients treated with ABA who had either chronic or resolved HBV infection.
 <sup>
  <xref rid="bibr78-1759720X20912646" ref-type="bibr">78</xref>
 </sup> All of the chronically infected patients received antiviral prophylaxis. No HBVr cases were identified in either group.
</p>
